✦ LIBER ✦

Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)

✍ Scribed by W. Yeo; M. Boyer; H. C. Chung; S. Y. K. Ong; R. Lim; Benny Zee; B. Ma; K. C. Lam; F. K. F. Mo; E. K. W. Ng; R. Ho; S. Clarke; J. K. Roh; P. Beale; S. Y. Rha; H. C. Jeung; R. Soo; B. C. Goh; A. T. C. Chan

Publisher: Springer
Year: 2006
Tongue: English
Weight: 266 KB
Volume: 59
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-006-0270-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A multi-center phase II study of S-1 plu

A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer

✍ Jae Jin Lee; Si-Young Kim; Hyun-Cheol Chung; Kyung-Hee Lee; Hong-Suk Song; Won-K 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 355 KB

A Multicenter Phase II Study of Docetaxe

A Multicenter Phase II Study of Docetaxel 60 mg/m2as First-Line Chemotherapy in Patients with Advanced or Recurrent Breast Cancer

✍ Takashi Ishikawa; Satoru Shimizu; Masaaki Inaba; Taro Asaga; Kiyohumi Katayama; 📂 Article 📅 2004 🏛 Springer Japan 🌐 English ⚖ 554 KB

Paclitaxel and carboplatin as first-line

Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group

✍ George Fountzilas; Dimitrios Pectasides; Anna Kalogera-Fountzila; Dimosthenis Sk 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 218 KB

Phase II study of pemetrexed disodium, a

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group

✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati